Osaic Holdings
ESPR

Osaic Holdings’s Esperion Therapeutics ESPR Stock Holding History

Osaic Holdings’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-40
Closed -$3.6K – 7462
2024
Q1 		$3.6K Buy
40
+5
+14% +$12 ﹤0.01% 6232
2023
Q4 		$3.5K Buy
+35
New +$45 ﹤0.01% 6318
2023
Q2 		– Sell
-18
Closed -$90 – 7489
2023
Q1 		$90 Sell
18
-2
-10% -$10 ﹤0.01% 7341
2022
Q4 		$2.5K Buy
+20
New +$143 ﹤0.01% 6595

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Osaic Holdings's ESPR Position: Q2 2026 in Review

Osaic Holdings reduced its Esperion Therapeutics (ESPR) stake by 8.3% in Q2 2026, selling an estimated $19.6K and leaving 77,434 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #4260.

Osaic Holdings first reported a position in ESPR in Q1 2020 and has held it in 26 quarters since. The position peaked at $526K in Q2 2020. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Osaic Holdings held 77,434 shares of Esperion Therapeutics worth $245K as of Q2 2026.
  • Osaic Holdings sold 7,000 Esperion Therapeutics shares in Q2 2026, an estimated $19.6K.
  • Esperion Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #4260 holding.
  • Osaic Holdings first reported a position in Esperion Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Esperion Therapeutics position peaked at $526K in Q2 2020.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.